The purpose of this study is to investigate metastatic pancreatic cancer. This study explores the use of an investigational medication combined with other treatments for this condition.
This study evaluates the safety and effectiveness of the investigational medication when used with chemotherapy. It focuses on how these treatments work together to address the condition.
- Who can participate: Adults aged 18 to 75 years with metastatic pancreatic cancer who have not received prior anti-tumor therapy can participate. Participants must have good organ function, an ECOG status of 0-1, measurable lesions, and an expected survival of at least 3 months.
- Study details: Participants will receive an investigational medication along with chemotherapy. Some may receive a placebo, an inactive substance that looks like the investigational medicine but does not contain any medicine. Participants will undergo regular assessments to monitor the effects of the treatment.
How understandable was the trial content above?
Hard to understand
Easy to understand